-
Mashup Score: 10
At HFSA 2022, Andrew Sauer, MD, provides perspective on contemporary trends in device therapy in heart failure, including recommendations made within the 2022 ACC/AHA/HFSA heart failure guidelines.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Viet Le, PA-C, details his experience at the Heart Failure Society of America annual meeting from the perspective of a physician assistant.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
@noshreza @HFSA @AHajduczok @MarkDrazner @MarkBelkinMD @SpencerCarter55 @stormigale @drkaushikjain @ShashankSinhaMD @EiranGorodeski @SelmaFMohammed Shameless plug for my take as a noobs to @hfsa meetings: #PhysicianAssociate #APPs #ACCCVT @practicalcardio @APAC_Cardiology @Intermountain https://t.co/IKT46Rvssc
-
-
Mashup Score: 1
Using National Inpatient Sample data from a nearly 2 decade period, investigators detail the increased risk of cardiovascular complications among women with PCOS during delivery hospitalizations and predictors of this increased risk.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
RT @SalmanZahidMD: Women with PCOS at Increased Risk of Cardiovascular Complications During Pregnancy @ErinMichos https://t.co/ORULv4sjnm…
-
-
Mashup Score: 0AAV Gene Therapy Shows Promise for Congestive Heart Failure - 2 year(s) ago
A first-in-human dose-escalation trial of a novel gene therapy suggests use was associated with clinically meaningful improvements in NYHA class and LVEF among patients with congestive heart failure.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
@CardioIAN #CardioTwitter https://t.co/8tpAoXxbIe
-
-
Mashup Score: 10
Viet Le, PA-C, discusses a study he led examining the tolerability and clinical impact of initiating combination therapy with SGLT2 inhibitors and GLP-1 RAs compared to monotherapy with either agent within Intermountain Healthcare.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
I am always happy to share good news. #Flozins + GLP1ra 😁🤣 #Flozinator #ACCCVT #CardioTwitter #CardioNephEndo @APAC_Cardiology @Intermountain @JBMuhlesteinMD @KirkKnowlton @ldjande3 @MDClone_ @ChristosArgyrop @hswapnil @DrMarthaGulati https://t.co/uT62AyDshk https://t.co/6agMuu2OiM
-
-
Mashup Score: 0TAVR Associated with Lower Risk of Valve Deterioration than SAVR - 2 year(s) ago
A large-scale analysis of data from a pair of RCTs and a nonrandomized registry provide insight into the risk of valve deterioration seen with TAVR vs SAVR and to what extent this might influence risk of mortality.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
@CardioIAN #CardioTwitter https://t.co/kK2WapfQF8
-
-
Mashup Score: 3TAVR Associated with Lower Risk of Valve Deterioration than SAVR - 2 year(s) ago
A large-scale analysis of data from a pair of RCTs and a nonrandomized registry provide insight into the risk of valve deterioration seen with TAVR vs SAVR and to what extent this might influence risk of mortality.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
Just presented at ACC2022: TAVR Associated with Lower Risk of Valve Deterioration than SAVR https://t.co/9S9EQ7LCK6 via @practicalcardio
-
-
Mashup Score: 0
Deepak Bhatt, MD, MPH, discusses the results of the interim analysis of the REVERSE-IT trial presented at AHA 2021, which indicates bentracimab provided immediate and sustained reversal of ticagrelor’s antiplatelet effects in patients requiring urgent surgery or experiencing major bleeding.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
REVERSE-IT: Bentracimab Shows Promise as Fast-Acting Ticagrelor Reversal Agent https://t.co/CzR1iBqwjX via @practicalcardio
-
-
Mashup Score: 5
Viet Le, PA-C, discusses the results of a study he led from AHA 2021 examining 10-year risk of MACE among patients with an LDL-C from 160-189 mg/dL compared to those with an LDL-C below 160 mg/dL.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
LDL-C Above 160 mg/dL Associated with Increased MACE Risk in Younger Patients https://t.co/cgveGTH5gx via @practicalcardio #AHA21 discussion continues beyond the conference. #Lipids #CardioTwitter #PAsDoThat #PhysicianAssociate @APAC_Cardiology
-
-
Mashup Score: 26
Deepak Bhatt, MD, MPH, provides perspective on the results of the REDUCE-IT PAD analysis he presented at the American Heart Association 2021 Scientific Sessions.
Source: Practical CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
RT @DLBHATTMD: REDUCE-IT PAD: Icosapent Ethyl Provides Consistent Benefit in PAD Patients https://t.co/S5N7djYTUS via @practicalcardio #PAD…
-
Trends in Device Therapy for Heart Failure Some thoughts shared at @HFSA @MRMehraMD @RyanTedfordMD @AHajduczok @FudimMarat @JasonKatzMD @NirUrielMD @gmac78 @ajaysmd @preventfailure @JavedButler1 @dranulala https://t.co/wERviuMKsO via @practicalcardio